News

Dual platform regenerative medicine company, Neuralstem, Inc., is wrapping up its participation in the 17th Annual BIO CEO & Investor Conference taking place February 9 to the 10th at the Waldorf Astoria in New York. President and CEO, Richard Garr, was invited to present…

Biopharmaceutical company Genervon recently reported observing improvements in a 46-year-old-man with advanced amyotrophic lateral sclerosis (ALS) taking the Company’s drug candidate GM604. The patient showed increased speech, swallowing and suction capabilities after a 12-week treatment. The drug, which has yet to be approved by the…

A recent study, titled, “Early detection of structural abnormalities and cytoplasmic accumulation of TDP-43 in tissue-engineered skins derived from ALS patients,” published in the journal, Acta Neuropathologica Communications, details the creation of a novel tissue-engineered skin model for amyotrophic lateral sclerosis (ALS). ALS is a progressive…

In a new study, researchers found the mechanism behind the degeneration of upper motor neurons in the brain, which current evidence has strongly linked to disease progression in patients suffering from amyotrophic lateral sclerosis (ALS). The findings were published in the journal Cerebral Cortex…

A research group at Duke University accomplished a pioneering feat in laboratory synthesis. They were able to grow the world’s first human muscle that is able to contract and respond to external stimuli, just like normal human tissue, and to respond to biochemical signals and pharmaceuticals. This new discovery can…

The ALS Society of Canada is proud to announce the first research project on amyotrophic lateral sclerosis (ALS) to receive funding raised from the viral ALS Ice Bucket Challenge. The Society also thanks the generous support of national non-profit organization, Brain Canada, and the Canadian Government. The Arthur J. Hudson Translational Team Grant will be used to…

A recent study published in the journal Molecular Cell, revealed that a specific domain in a particular heat-shock protein plays a major role in the degradation of misfolded proteins. The study is entitled “The Hsp104 N-Terminal Domain Enables Disaggregase Plasticity and Potentiation”. Disorders such…

A team of researchers from the Penn State College of Medicine found that a specific gene variant found in a third of patients with Amyotrophic lateral sclerosis (ALS) is associated with faster disease progression. The results were found in mice models of ALS carrying only this gene variant,…

Last November, Dr. Piera Pasinelli, Ph.D., associate professor of neuroscience and Co-Director of the Weinberg Unit for ALS Research at Thomas Jefferson University, and her research team made an important discovery in the field of amyotrophic lateral sclerosis (ALS) research that may change the way the therapeutic protocols…

A new study entitled “HDAC6 Is a Bruchpilot Deacetylase that Facilitates Neurotransmitter Release” was published in Cell Reports by Katarzyna Miskiewicz and Liya E. Jose, co-first authors of the study and part of Dr. Patrik Verstreken’s group from the VIB Center for the…